A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

In the present invention there is described a pharmaceutical composition containing 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione that means the compound of the general formula (I) or a pharmaceutically acceptable derivative thereof submaximal amount of composition for support of insulin secretion being selected from the group consisting of glibenclamide glipizide gliclazide and glimepiride and a pharmaceutically acceptable carrier. There is also described ...

In the present invention there is disclosed a pharmaceutical combination containing 2 to 8 mg of 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidine-24-dione (compound of the general formula I) or a tautomeric form and/or pharmaceutically acceptable derivative thereof and sulfonylurea wherein the sulfonylurea is represented by glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. There is also disclosed the use of the above-described combination in a pharmaceutica...

Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal with positive effect by glycemic control without observable unfavourable effects which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione (Compound I) or a pharmaceutically acceptable salt thereof and sulfonyl urea. 2. A method according to Claim 1 wherein the c is glibenclamide glipizide gliclazide glimepiride tola...